SERDA Therapeutics
SERDA Therapeutics is a clinical stage biopharmaceutical company focused on developing innovative solutions for wound care, particularly in the treatment of burn injuries and chronic ulcers. The company aims to provide fast and effective therapeutic debridement through its proprietary enzymatic product, SN514, which is designed to enhance healing by selectively removing necrotic tissue.
Industries
Nr. of Employees
small (1-50)
SERDA Therapeutics
Paasheuvelweg 25, 1105 BP Amsterdam, the Netherlands.
Products
Prescription enzymatic hydrogel debridement agent (developmental)
A developmental topical prescription product comprising a proteolytic enzyme in a hydrogel intended to rapidly degrade necrotic tissue (including collagen and fibrin), enable wound healing, and be applied without surgical intervention; designed for burn injuries and chronic ulcers.
Prescription enzymatic hydrogel debridement agent (developmental)
A developmental topical prescription product comprising a proteolytic enzyme in a hydrogel intended to rapidly degrade necrotic tissue (including collagen and fibrin), enable wound healing, and be applied without surgical intervention; designed for burn injuries and chronic ulcers.
Expertise Areas
- Enzymatic debridement therapeutics
- Hydrogel formulation for topical applications
- Preclinical wound model testing
- Early-phase clinical trial management
Key Technologies
- Proteolytic enzyme therapeutics
- Hydrogel drug delivery formulations
- In vitro biofilm assays
- Preclinical wound models
Key People
News & Updates
Completion of the first Phase 1 clinical study of SN514, a key product in their development pipeline.
Initiation of the Phase 1 clinical study of SN514, aimed at addressing major unmet clinical needs.
Completion of a € 2 million funding round to support the development of their enzymatic wound debridement product.
Submission of an Investigational New Drug (IND) application for their lead product, SN514.
Completion of the first Phase 1 clinical study of SN514, a key product in their development pipeline.
Initiation of the Phase 1 clinical study of SN514, aimed at addressing major unmet clinical needs.
Completion of a € 2 million funding round to support the development of their enzymatic wound debridement product.
Submission of an Investigational New Drug (IND) application for their lead product, SN514.